Scilex Holding Company
Scilex, a Sorrento subsidiary, responsibly develops and commercializes branded pharmaceutical products globally.
Founded
2012Scilex, a Sorrento subsidiary, responsibly develops and commercializes branded pharmaceutical products globally.
Scilex Holding Company, a subsidiary of Sorrento, is dedicated to developing and commercializing branded pharmaceutical products with a focus on non-opioid pain management. Located in Palo Alto and San Diego, California, Scilex leverages advanced adhesion and delivery systems, including proprietary patch technology and anti-inflammatory oral solutions, to optimize drug delivery and improve quality of life. Their market focus includes precision dosing for high-risk patients and fast-acting migraine relief.
Scilex has achieved recognition for its innovative approach to pain management, particularly through its proprietary technologies that enhance drug delivery efficacy. As a public company listed on Nasdaq (SCLX), Scilex continues to make significant strides in the pharmaceutical industry, contributing to the global effort to provide safer, non-opioid pain relief options. Their impact is underscored by their commitment to responsible development and commercialization of high-quality pharmaceutical products.
Companies similar to Scilex Holding Company include Scienture, Sollis Therapeutics, Escient Pharmaceuticals and AcelRx Pharmaceuticals.
Scilex Holding Company was founded in 2012.
Scilex Holding Company's headquarters is located in Palo Alto, CA, US.
Scilex Holding Company's most recent funding round was for $25M (USD) in March 2023.
As of Mar 21, 2023, Scilex Holding Company has disclosed funding of $32.5M (USD). Undisclosed round amounts are excluded.
Scilex Holding Company has 95 employees as of Feb 10, 2024.
AcelRx Pharmaceuticals
